

Index

Locators in **bold** refer to tables; those in *italic* to figures

- absolute neutrophil count (ANC)
 benign ethnic neutropenia populations **143**
 clozapine 29, 31, **142, 143**
 general population **142**
- acamprosate, alcohol use disorder **93**
- acetylcholinesterase inhibitors (AChEIs) 99,
100–101
- acute mania *see* mania
- ADHD (attention deficit hyperactivity disorder),
 evaluation instruments for children/
 adolescents **62–64**
- adolescents *see* children/adolescents
- affective disorders, children/adolescents **62–64**
- agitation algorithm *see* psychomotor agitation
 algorithm
- aggression and violence xxii, 38, 40; *see also*
 impulsive; predatory *and* psychotic
 aggression
- categorization 24, **38**
- role of long-acting injectable antipsychotics
 16
- SAD-BT patients 42–43
- schizophrenia 24–25, **25–26, 27**
- substance use disorders 87
- treatment approaches 38–40
- akathisia
- adverse drug effects **106, 110, 114, 118, 122,**
126, 130, 134, 155, 166, 176, 181, 186,
191, 196, 239, 243, 247, 257, 262, 266,
270, 274, 278, 283, 287, 351
- aggression/violence causation 39
- anxiety in schizophrenia patients 52, **52**
- benzodiazepine use in **345, 346, 355, 359,**
366, 378, 382
- drug plasma concentrations 20
- psychomotor agitation 505
- treatments **4, 5, 35, 295, 296, 298**
- alcohol use disorder
 and risk of psychotic illness **86–87**
 treatment approaches **92, 93**
- Alcohol Use Disorders Identification Test (AUDIT)
90
- algorithm, psychomotor agitation *see*
 psychomotor agitation
- alprazolam **345**
 art of psychopharmacology/pearls **348**
 dosages and kinetics **347**
- drug interactions **249, 254, 348**
- initial workup/laboratory tests **347**
- mechanisms of action **346**
- medication-related psychosis **67–68**
- plasma concentrations **346**
- treatment monitoring **347**
- treatment response and side effects **346**
- Alzheimer's disease (AD), behavioral
 disturbances 99
- amantadine **200**
 art of psychopharmacology/pearls **203**
 behavioral disturbances **100–101**
 dosages and kinetics **202**
 drug interactions **203, 293, 467**
 initial workup/laboratory tests **202**
 mechanisms of action **201**
 plasma concentrations **201**
 psychomotor agitation 505
 treatment monitoring **202**
 treatment response and side effects **201**
- American Academy of Child and Adolescent
 Psychiatry recommendations, childhood
 psychosis **71**
- amitriptyline **304**
 art of psychopharmacology/pearls **307**
 dosages and kinetics **306**
 drug interactions **306, 480, 501**
 initial workup/laboratory tests **305**
 mechanisms of action **304**
 medication-related psychosis **67**
 plasma concentrations **305**
 treatment monitoring **305**
 treatment response and side effects **305**
- amphetamines
 medication-related psychosis **67–68, 86–87**
 urine sampling 88–89
- ANC *see* absolute neutrophil count
- anticholinergics, medication-related psychosis
67–69
- anticonvulsants, behavioral disturbances 99, **100–101**
- antidepressants; *see also* SSRIs; tricyclic
 antidepressants *and see specific drugs*
 behavioral disturbances **100–101**
 contraindications for bipolar disorder 35, 39,
 47, 51, 52, 54
 depressed and suicidal schizophrenia 34, **35**
 drug interactions **501**

- primary anxiety/depression in schizophrenia 54
 antiepileptics, medication-related psychosis
 67–68
- antihistaminic medications, sleep disturbance in
 schizophrenia spectrum disorders **57–58**
- antipsychotics **5, 6, 10, 23**; *see also* atypical
 antipsychotics; long-acting injectable
 antipsychotics *and see specific drugs*
- adherence issues 16
- aggression/violence **25–26**
- augmented with ECT 80–81
- behavioral disturbances 99, **100–101**
- children/adolescents 71–74
- combination regimens 23
- depressed and suicidal schizophrenia 34, **35**
- drug interactions **501**
- geriatric patients 7
- neurocognitive disorder with psychosis 7
- plasma concentrations **12–13, 489**
- positive psychotic symptoms **6**
- PRN and STAT medications **9**
- psychomotor agitation 503–505
- SAD-BT patients – acute manic phase 42, **43**
- SAD-BT patients – maintenance phase 45–47,
 47–**48**
- substance use disorders 91
- anxiety disorders xxii, 51, 54
- akathisia 52, 52
- association with bipolar diathesis in SAD-BT 53
- benzodiazepine contraindications 53–54
- children/adolescents **62–64, 64**
- differential diagnosis 51, 51, 53, 54
- as predictor of relapse 51–52
- treating primary anxiety 54
- aripiprazole **185**
- art of psychopharmacology/pearls **189**
- children/adolescents **73–74**
- contraindications/medical precautions **189**
- dosages and kinetics **18–19, 45–46, 188**
- drug interactions **188**
- geriatric patients 7
- initial workup/laboratory tests **187**
- long-acting injectable **16–18, 18–19, 45–46**
- mechanisms of action **186**
- plasma concentrations **186, 489**
- plasma levels relative to drug dosage **12–13**
- polypharmacy/combination regimens 23
- treating elevated prolactin levels **497–498**
- treatment monitoring **187**
- treatment response and side effects **186**
- armodafinil **434**
- art of psychopharmacology/pearls **439**
- dosages and kinetics **437**
- drug interactions **438**
- initial workup/laboratory tests **436**
- mechanisms of action **434**
- plasma concentrations **435**
- treatment monitoring **437**
- treatment response and side effects **435**
- asenapine **133**
- art of psychopharmacology/pearls **136**
- dosages and kinetics **136**
- drug interactions **136**
- initial workup/laboratory tests **135**
- mechanisms of action **134**
- plasma concentrations **134**
- treatment monitoring **135**
- treatment response and side effects **134**
- Asian patients, Stevens-Johnson Syndrome 98
- aspirin, medication-related psychosis **67–68**
- atomoxetine **404**
- art of psychopharmacology/pearls **407**
- dosages and kinetics **406**
- drug interactions **249, 259, 263, 293, 407,**
412–413
- initial workup/laboratory tests **405**
- mechanisms of action **404**
- plasma concentrations **405**
- treatment monitoring **406**
- treatment response and side effects **405**
- attention deficit hyperactivity disorder *see* ADHD
- atypical antipsychotics
- behavioral disturbances **100–101**
- children/adolescents 71, 74
- autism spectrum disorders, children/adolescents
 differential diagnoses 64–65
- evaluation instruments **62–64**
- autoimmune disorders, psychosis in children/
 adolescents **68–69**
- B vitamin deficiencies, children/adolescents **70**
- barbiturates, urine sampling **88–89**
- behavioral disturbances xxii, 98, 101
- in dementia/neurocognitive disorders 99
- initial evaluation 3–4, **4**
- psychopharmacological approaches **100–101**
- in traumatic brain injury 98–99
- benign ethnic neutropenia (BEN) **141, 143**
- benzodiazepines; *see also specific drugs*
- aggression/violence 39
- behavioral disturbances 99, **100–101**
- contraindications for schizophrenia 51, 52,
 53–54, 56
- medication-related psychosis **67–68**
- urine sampling **88–89**
- benzodiazepine receptor agonists *see* Z-drugs
- benztropine **204**
- art of psychopharmacology/pearls **207**
- dosages and kinetics **206**
- drug interactions **141, 163, 206**

- benztropine (cont.)
 initial workup/laboratory tests **205**
 mechanisms of action **204**
 plasma concentrations **204**
 treatment monitoring **206**
 treatment response and side effects **204, 205**
- beta blockers; *see also specific drugs*
 drug interactions **455, 462, 473, 480**
 medication-related psychosis **67–68**
 positive psychotic symptoms **8**
- bipolar depression **35, 35**
- bipolar disorder; *see also mania; schizoaffective disorder*
 antidepressant contraindications **35, 39, 47, 51, 52, 54**
 children/adolescents **62–64**
- BLT (bright light therapy) **82–83**
- brexipiprazole
 art of psychopharmacology/pearls **193**
 contraindications/medical precautions **193**
 dosages and kinetics **193**
 drug interactions **193**
 initial workup/laboratory tests **192**
 mechanisms of action **190**
 plasma concentrations **191**
 treatment monitoring **192**
 treatment response and side effects **191**
- bright light therapy (BLT) **82–83**
- buprenorphine, opioid use disorder **94**
- bupropion **290**
 art of psychopharmacology/pearls **293**
 dosages and kinetics **292**
 drug interactions **293**
 initial workup/laboratory tests **291**
 mechanisms of action **290**
 plasma concentrations **291**
 tobacco use disorder **91–92**
 treatment monitoring **292**
 treatment response and side effects **291**
- buspirone **350**
 art of psychopharmacology/pearls **353**
 behavioral disturbances **100–101**
 dosages and kinetics **352**
 drug interactions **249, 352**
 initial workup/laboratory tests **351**
 mechanisms of action **350**
 plasma concentrations **351**
 treatment monitoring **352**
 treatment response and side effects **351**
- cannabis
 children/adolescents **65–66, 65–67**
 and risk of psychotic illness **86, 86–87**
 screening tools/evaluation instruments **87–88, 88–89**
- treatment approaches **95**
 urine sampling **88–89**
- carbamazepine **217**
 art of psychopharmacology/pearls **221**
 contraindications/medical precautions **98, 220**
 cytochrome P450 induction/inhibition **492**
 dosages and kinetics **219**
 drug interactions **220**
 initial workup/laboratory tests **219**
 mechanisms of action **218**
 plasma concentrations **13, 14, 218, 490**
 SAD-BT patients **42, 44–45**
 treatment monitoring **219**
 treatment response and side effects **218**
- cariprazine **195**
 art of psychopharmacology/pearls **198**
 contraindications/medical precautions **198**
 dosages and kinetics **198**
 drug interactions **198**
 initial workup/laboratory tests **197**
 mechanisms of action **196**
 plasma concentrations **196**
 SAD-BT patients **47–48**
 treatment monitoring **197**
 treatment response and side effects **196**
- CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) project **86**
- CBT *see* cognitive behavioral therapy
- cephalosporins, medication-related psychosis **67–68**
- childhood-onset schizophrenia (COS) **61**
- Child-Pugh hepatic function scoring **495; see also specific drugs** (dosages and kinetics)
- children/adolescents xxii, **60, 75**
 antipsychotic medication comparisons **73–74**
 assessment recommendations **71**
 atypical antipsychotics **71–73, 74**
 childhood-onset schizophrenia **61**
 Cognitive Enhancement and Remediation **75, 75**
 differential diagnoses **61, 62–65**
 early-onset schizophrenia **61**
 etiologies of youth psychosis **62**
 evaluation instruments **62–64**
 evaluation/diagnostic tests **70, 70**
 medication-related psychosis **67–68, 68–69**
 neurodevelopmental disorders **64–65**
 psychiatric conditions **62–64**
 psychosocial interventions **74–75, 75**
 substance use disorders **65–66, 66–67**
 TEOS study **73**
- chlorpromazine
 art of psychopharmacology/pearls **108**
 children/adolescents **73–74**
 dosages and kinetics **107**
 drug interactions **107, 412–413, 431–432**
 initial workup/laboratory tests

- mechanisms of action
- plasma concentrations **106**
- treatment monitoring **107**
- treatment response and side effects **106**
- circadian rhythm modulators 57, **57**
- citalopram **238**
 - art of psychopharmacology/pearls **241**
 - behavioral disturbances **100–101**
 - dosages and kinetics **240**
 - drug interactions **240**, 501
 - initial workup/laboratory tests **239**
 - mechanisms of action **238**
 - medication-related psychosis **67–68**
 - plasma concentrations **239**
 - treatment monitoring **240**
 - treatment response and side effects **239**
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project 86
- clomipramine **308**
 - art of psychopharmacology/pearls **311**
 - dosages and kinetics **310**
 - drug interactions **254, 310, 438, 501**
 - initial workup/laboratory tests **309**
 - mechanisms of action **308**
 - medication-related psychosis **67–68**
 - plasma concentrations **309**
 - treatment monitoring **310**
 - treatment response and side effects **309**
- clonazepam **354**
 - anxiety in schizophrenia patients 52
 - art of psychopharmacology/pearls **357**
 - dosages and kinetics **356**
 - drug interactions **356**
 - initial workup/laboratory tests **355**
 - mechanisms of action **354**
 - medication-related psychosis **67–68**
 - plasma concentrations **355**
 - positive psychotic symptoms 8
 - psychomotor agitation **504**
 - treatment monitoring **356**
 - treatment response and side effects **355**
- clonidine **476**
 - art of psychopharmacology/pearls **481**
 - dosages and kinetics **479**
 - drug interactions **425, 480**
 - geriatric patients 7
 - initial workup/laboratory tests **478**
 - mechanisms of action **477**
 - plasma concentrations **477**
 - treatment monitoring **479**
 - treatment response and side effects **477, 478**
- clozapine **137**
 - absolute neutrophil count **29, 31, 142, 143**
 - aggression/violence 24–26, 27, 38, 39–40, 40
 - art of psychopharmacology/pearls **144**
 - augmented with ECT 80–81
 - benign ethnic neutropenia populations **143**
 - bipolar diathesis **28**
 - children/adolescents 71–74
 - contraindications/medical precautions **141**
 - depressed and suicidal schizophrenia 34
 - dosages and kinetics **140**
 - drug interactions **141, 383**
 - geriatric patients 7
 - as gold standard treatment 23
 - initial workup/laboratory tests **139**
 - initiation of treatment 28–31, **30**
 - mania 27
 - mechanisms of action **138**
 - motivational interviewing 32
 - plasma concentrations **12–13, 138, 489**
 - polypharmacy/combination regimens 23
 - response rates **23, 23**
 - suicidality 24
 - treatment maintenance 31, **32**
 - treatment monitoring **29, 31, 32, 140**
 - treatment resistance 80
 - treatment response and side effects **138, 139**
- CNS infections, psychosis in children/adolescents **68–69**
- cocaine use disorder
 - and risk of psychotic illness **86–87**
 - treatment approaches 95
 - urine sampling **88–89**
- cognitive behavioral therapy (CBT), children/adolescents 75
- Cognitive Enhancement and Remediation 75, **75**
- combination regimens *see* polypharmacy
- complex disorders **xxi**
- constipation, management **493**
- corticosteroids, medication-related psychosis **67–68**
- COS (childhood-onset schizophrenia) 61
- CRAFFT (Car; Relax; Alone; Forget; Friends; Trouble) questionnaire, substance use disorders **90**
- crime 16, 18; *see also* aggression and violence
- cytochrome P450 (CYP) system
 - carbamazepine 42
 - common inducers and inhibitors **492**
 - tobacco use disorder 92
- date rape drug, GHB 65
- deep brain stimulation (DBS) 82, 83
- delirium, psychosis in children/adolescents **68–69**
- dementia
 - behavioral disturbances 99
 - positive psychotic symptoms 7, 7
- depot *see* long-acting injectable antipsychotics

- depression; *see also* suicidality
 bipolar **35, 35**
 evaluation instruments for children/
 adolescents **62–64**
 treating primary depression in schizophrenia
 54
- desipramine **312**
 art of psychopharmacology/pearls **315**
 dosages and kinetics **314**
 drug interactions **314, 412–413, 418–419,**
431–432, 501
 initial workup/laboratory tests **313**
 mechanisms of action **312**
 medication-related psychosis **67–68**
 plasma concentrations **313**
 treatment monitoring **313**
 treatment response and side effects **313**
- desvenlafaxine **273**
 art of psychopharmacology/pearls **276**
 dosages and kinetics **275**
 drug interactions **275**
 initial workup/laboratory tests **274**
 mechanisms of action **273**
 plasma concentrations **274**
 treatment monitoring **275**
 treatment response and side effects **274**
- dextroamphetamine **408**
 art of psychopharmacology/pearls **413**
 dosages and kinetics **411**
 drug interactions **412–413**
 initial workup/laboratory tests **410**
 mechanisms of action **408**
 plasma concentrations **409**
 treatment monitoring **411**
 treatment response and side effects **409**
- dextromethorphan/quinidine **446**
 art of psychopharmacology/pearls **451**
 dosages and kinetics **449**
 drug interactions **450, 501**
 initial workup/laboratory tests **448**
 mechanisms of action **446**
 plasma concentrations **447**
 treatment monitoring **449**
 treatment response and side effects **447**
 use in children/adolescents **65, 66–67**
- diazepam **358**
 art of psychopharmacology/pearls **361**
 dosages and kinetics **360**
 drug interactions **236, 249, 254, 360**
 initial workup/laboratory tests **88–89, 359**
 mechanisms of action **358**
 medication-related psychosis **67–68**
 plasma concentrations **359**
 treatment monitoring **359**
 treatment response and side effects **359**
- diphenhydramine **208**
 art of psychopharmacology/pearls **211**
 dosages and kinetics **210**
 drug interactions **211**
 initial workup/laboratory tests **210**
 mechanisms of action **209**
 plasma concentrations **209**
 positive psychotic symptoms **9**
 psychomotor agitation **504**
 treatment monitoring **210**
 treatment response and side effects **209**
- direct current stimulation **36**
- disulfiram, alcohol use disorder **93**
- divalproex
 plasma concentrations **13, 14, 490**
 SAD-BT patients – acute manic phase **44–45**
- DMX *see* dextromethorphan/quinidine
- donepezil **452**
 art of psychopharmacology/pearls **456–457**
 dosages and kinetics **454**
 drug interactions **455**
 initial workup/laboratory tests **454**
 mechanisms of action **452**
 plasma concentrations **453**
 treatment monitoring **454**
 treatment response and side effects **453**
- dopamine antagonists/partial agonists; *see also*
specific drugs (mechanism of action)
 behavioral disturbances **100–101**
 long-acting injectable antipsychotics **18**
 psychotic aggression and violence **39**
 tobacco use disorder **91–92**
- dopamine hypothesis, positive psychotic
 symptoms **3**
- doxepin **316**
 art of psychopharmacology/pearls **319**
 dosages and kinetics **318**
 drug interactions **318**
 initial workup/laboratory tests **317**
 mechanisms of action **316**
 plasma concentrations **317**
 treatment monitoring **318**
 treatment response and side effects **317**
- Drug Abuse Screening Test (DAST-10) **90**
- duloxetine **277**
 art of psychopharmacology/pearls **280**
 dosages and kinetics **279**
 drug interactions **280, 412–413, 501**
 initial workup/laboratory tests **278**
 mechanisms of action **277**
 plasma concentrations **278**
 treatment monitoring **279**
 treatment response and side effects **278**

- early-onset schizophrenia (EOS) 61
 ecstasy *see* MDMA
 electroconvulsive therapy (ECT) xxii, 80, 83
 depressed and suicidal patients 36
 indications 80
 psychotic aggression and violence 39
 relapse prevention 81
 in treatment-resistant patients 80–81
 electrolyte imbalances, psychosis in children/
 adolescents **68–69**
 endocrine disorders, psychosis in children/
 adolescents **68–69**
 escitalopram **242**
 aggression/violence 99
 art of psychopharmacology/pearls **244**
 behavioral disturbances **100–101**
 dosages and kinetics **244**
 drug interactions **244, 501**
 initial workup/laboratory tests **243**
 mechanisms of action **242**
 medication-related psychosis **67–68**
 plasma concentrations **243**
 treatment monitoring **244**
 treatment response and side effects **243**
 eszopiclone **56–57, 371**
 art of psychopharmacology/pearls **374**
 dosages and kinetics **373**
 drug interactions **373**
 initial workup/laboratory tests **372**
 mechanisms of action **371**
 plasma concentrations **372**
 psychomotor agitation 304
 treatment monitoring **372**
 treatment response and side effects **372**
 evaluation instruments *see* screening tools
 Fagerström Test for Nicotine Dependence **90**
 FDA-approved atypical antipsychotics **74**
 fentanyl, drug interactions **501**
 fluoxetine **246**
 art of psychopharmacology/pearls **249**
 contraindications/medical precautions 54
 dosages and kinetics **248**
 drug interactions **249, 412–413, 501**
 initial workup/laboratory tests **248**
 mechanisms of action **247**
 plasma concentrations **247**
 SAD-BT patients – maintenance phase **47–48**
 treatment monitoring **248**
 treatment response and side effects **247**
 fluphenazine
 art of psychopharmacology/pearls **112**
 children/adolescents **73–74**
 dosages and kinetics **18–19, 45–46, 111**
 drug interactions **112**
 initial workup/laboratory tests **110**
 long-acting injectable **6, 16–18, 18–19, 45–46**
 mechanisms of action **109**
 plasma concentrations **110, 489**
 plasma levels relative to drug dosage **12–13**
 positive psychotic symptoms **6**
 psychomotor agitation 505
 SAD-BT patients **43**
 treatment monitoring **111**
 treatment response and side effects **110**
 fluoroquinolones, medication-related psychosis
 67–68
 fluvoxamine **251**
 art of psychopharmacology/pearls **254**
 dosages and kinetics **253**
 drug interactions **136, 141, 148, 254, 501**
 initial workup/laboratory tests **252**
 mechanisms of action **251**
 medication-related psychosis **67–68**
 plasma concentrations **252**
 treatment monitoring **253**
 treatment response and side effects **252**
 forensic populations *see* crime; aggression and
 violence
 gabapentin, alcohol use disorder **93**
 galantamine **458**
 art of psychopharmacology/pearls **463**
 dosages and kinetics **461**
 drug interactions **462**
 initial workup/laboratory tests **460**
 mechanisms of action **458**
 plasma concentrations **459**
 treatment monitoring **460**
 treatment response and side effects **459**
 genetic disorders in children/adolescents **64–65,**
 68–69
 geriatric patients, positive psychotic symptoms **7, 7**
 GHB (gamma-hydroxybutyrate), use in children/
 adolescents **65, 66–67**
 glutamate hypothesis, positive psychotic
 symptoms **3**
 guanfacine **482**
 art of psychopharmacology/pearls **486**
 dosages and kinetics **485**
 drug interactions **485**
 geriatric patients **7**
 initial workup/laboratory tests **484**
 mechanisms of action **482**
 plasma concentrations **483**
 treatment monitoring **484**
 treatment response and side effects **483**
 guidelines, limitations of **88**

- hallucinogens, and risk of psychotic illness **86–87**
 haloperidol **113**
 aggression in schizophrenia patients 24–25, 27
 art of psychopharmacology/pearls **116**
 children/adolescents **73–74**
 dosages and kinetics 18–19, **45–46**, **115**
 drug interactions **116**
 initial workup/laboratory tests **114**
 long-acting injectable **6**, **16–18**, 18–19, 45–46
 mechanisms of action **113**
 plasma concentrations **114**, **489**
 plasma levels relative to drug dosage **12–13**
 positive psychotic symptoms **6**
 psychomotor agitation 505
 SAD-BT patients **43**
 treatment monitoring **115**
 treatment response and side effects **114**
 harm reduction approaches, substance use disorders 90
 heroin, urine sampling **88–89**
 homelessness 94
 hydroxyzine **362**
 art of psychopharmacology/pearls **364**
 dosages and kinetics **364**
 drug interactions **364**
 initial workup/laboratory tests **363**
 mechanisms of action **362**
 plasma concentrations **363**
 positive psychotic symptoms **9**
 treatment monitoring **363**
 treatment response and side effects **363**
- iatrogenic/medication-related psychosis **67–68**
 iloperidone **145**
 art of psychopharmacology/pearls **149**
 contraindications/medical precautions **148**
 dosages and kinetics **148**
 drug interactions **148**
 initial workup/laboratory tests **147**
 mechanisms of action **146**
 plasma concentrations **146**
 treatment monitoring **147**
 treatment response and side effects **146**
 imaginary friends 61
 imipramine **320**
 art of psychopharmacology/pearls **323**
 dosages and kinetics **322**
 drug interactions **254**, **322**, **501**
 initial workup/laboratory tests **321**
 mechanisms of action **320**
 medication-related psychosis **67–68**
 plasma concentrations **321**
 treatment monitoring **322**
 treatment response and side effects **321**
- impulsive aggression/violence 24, 38, 39–40
 infections, psychosis in children/adolescents **68–69**
 insomnia and sleep disturbance xxii, 56, 58
 circadian rhythm modulators 57, **57**
 orexin receptor antagonists 57
 other treatments 57–58
 systematic approach to **58**
 Z-drugs 56–57, **57**
 instrumental aggression/violence 24, 38, 38, 40
 InterSePT study, suicidality in treatment-resistant schizophrenia 24, 24
 isocarboxazid **328**
 art of psychopharmacology/pearls **330**
 dosages and kinetics **330**
 drug interactions **330**
 initial workup/laboratory tests **329**
 mechanisms of action **328**
 plasma concentrations **329**
 treatment monitoring **329**
 treatment response and side effects **329**
- Kane Criteria, treatment resistance 22
 ketamine, use in children/adolescents 65, 66–67
 kinetics, long-acting injectable antipsychotics 18–19, **18**, **45–46**; *see also specific drugs* (dosages and kinetics)
- laboratory testing; *see also specific drugs* (initial workup/laboratory tests)
 psychosis in children/adolescents **70**
 substance use disorders 88–89, **89**
 LAIs *see* long-acting injectable antipsychotics
 lamotrigine **222**
 art of psychopharmacology/pearls **226**
 bipolar depression **35**
 contraindications/medical precautions **226**
 dosages and kinetics **224–225**
 drug interactions **226**
 initial workup/laboratory tests **224**
 mechanisms of action **223**
 plasma concentrations **223**
 SAD-BT patients – acute manic phase 44–45
 treatment monitoring **224**
 treatment response and side effects **223**
- lemborexant 57
 levomilnacipran **282**
 art of psychopharmacology/pearls **284**
 dosages and kinetics **284**
 drug interactions **284**, **501**
 initial workup/laboratory tests **283**
 mechanisms of action **282**
 plasma concentrations **282**
 treatment monitoring **283**

- treatment response and side effects **282, 283**
- light therapy 82–83
- lisdexamfetamine **415**
 - art of psychopharmacology/pearls **419**
 - dosages and kinetics **418**
 - drug interactions **418–419**
 - initial workup/laboratory tests **417**
 - mechanisms of action **415**
 - plasma concentrations **416**
 - treatment monitoring **417**
 - treatment response and side effects **416**
- lithium **228**
 - art of psychopharmacology/pearls **232**
 - behavioral disturbances **100–101**
 - bipolar depression **35**
 - contraindications/medical precautions **232**
 - depressed and suicidal schizophrenia 34
 - dosages and kinetics **231**
 - drug interactions **231**
 - geriatric patients **7**
 - initial workup/laboratory tests **230**
 - loading **496**
 - mechanisms of action **229**
 - plasma concentrations 13, **14, 229, 490**
 - psychomotor agitation 504, 505
 - psychotic aggression and violence 39
 - SAD-BT patients – acute manic phase 42–45, **45**
 - treatment monitoring **230**
 - treatment response and side effects **229**
- long-acting injectable antipsychotics (LAIs) xxii, 16, 20
 - children/adolescents **73–74**
 - depressed and suicidal schizophrenia patients 34
 - initiation strategies **16–18**
 - kinetics of 18–19, **18, 45–46**
 - plasma drug concentration measurements 20, **20**
 - positive psychotic symptoms 6
 - SAD-BT patients 42, **43**
- lorazepam **365**
 - art of psychopharmacology/pearls **368**
 - dosages and kinetics **367**
 - drug interactions **368**
 - initial workup/laboratory tests **366**
 - mechanisms of action **365**
 - medication-related psychosis **67–68**
 - plasma concentrations **366**
 - positive psychotic symptoms **9**
 - treatment monitoring **367**
 - treatment response and side effects **366**
- lowest effective dose
 - clonazepam **356**
 - children/adolescents 71–73, **75**
 - psychomotor agitation 505
 - loxapine **117**
 - art of psychopharmacology/pearls **120**
 - children/adolescents **73–74**
 - dosages and kinetics **119**
 - drug interactions **119**
 - initial workup/laboratory tests **118**
 - mechanisms of action **117**
 - plasma concentrations **118**
 - treatment monitoring **119**
 - treatment response and side effects **118**
- LSD (lysergic acid diethylamine) 65, **66–67, 501**
- lumateperone **150**
 - art of psychopharmacology/pearls **153**
 - contraindications/medical precautions **153**
 - dosages and kinetics **152**
 - drug interactions **152, 501**
 - initial workup/laboratory tests **151**
 - mechanisms of action **150**
 - plasma concentrations **151**
 - treatment monitoring **152**
 - treatment response and side effects **151**
- lurasidone **154**
 - art of psychopharmacology/pearls **158**
 - bipolar depression **35**
 - children/adolescents **73–74**
 - contraindications/medical precautions **157**
 - dosages and kinetics **157**
 - drug interactions **157**
 - initial workup/laboratory tests **156**
 - mechanisms of action **155**
 - plasma concentrations **155**
 - SAD-BT patients – maintenance phase 47–48
 - treatment monitoring **156**
 - treatment response and side effects **155**
- mania; *see also* bipolar disorder
 - asenapine **133**
 - benzodiazepines **345, 354, 365**
 - brexpirazole
 - carbamazepine **217, 221**
 - cariprazine **195**
 - drug plasma concentrations 13, **14, 490**
 - lamotrigine **226**
 - lithium loading **496**
 - lurasidone **154**
 - olanzapine **159**
 - paliperidone **165**
 - psychomotor agitation 504
 - quetiapine **170, 173, 175**
 - risperidone **175**
 - SAD-BT patients 42–45, **45**
 - treatment-resistant 27, 28
 - ziprasidone **180**

- MAOIs (monoamine oxidase inhibitors); *see also specific drugs*
 dietary restrictions **499–500**
 drug interactions risking serotonin syndrome **501**
- MATRICES Consensus Cognitive Battery (MCCB)
 81
- maximum response thresholds *see* point of futility
- MDMA (methylenedioxyamphetamine)/ecstasy
 drug interactions **501**
 urine sampling **88–89**
 use in children/adolescents **65, 66–67**
- measurement instruments *see* screening tools
- medication *see* psychopharmacological approaches
- medication-related psychosis, children/adolescents **67–68**
- melatonin **58, 393**
 art of psychopharmacology/pearls **396**
 dosages and kinetics **395**
 drug interactions **395**
 initial workup/laboratory tests **394**
 mechanisms of action **393**
 neurotransmitters/receptors **393, 397**
 plasma concentrations **394**
 schizophrenia spectrum disorders **57, 57**
 treatment monitoring **394**
 treatment response and side effects **394**
- memantine **465**
 art of psychopharmacology/pearls **468**
 dosages and kinetics **467**
 drug interactions **467**
 geriatric patients **7**
 initial workup/laboratory tests **466**
 mechanisms of action **465**
 plasma concentrations **466**
 treatment monitoring **467**
 treatment response and side effects **466**
- metabolic disorders, psychosis in children/adolescents **68–69**
- methadone **94**
- methamphetamine
 children/adolescents **65, 66–67**
 and risk of psychotic illness **86**
 treatment approaches **95**
- methylphenidate **421**
 art of psychopharmacology/pearls **426**
 dosages and kinetics **424**
 drug interactions **425, 438, 444**
 initial workup/laboratory tests **423**
 mechanisms of action **422**
 plasma concentrations **422**
 treatment monitoring **424**
 treatment response and side effects **422**
- migraine
 drug interactions **501**
 induced psychosis in children/adolescents **68–69**
 medication *see* guanfacine; valproic acid; venlafaxine
- minimal response thresholds, plasma concentrations **12–13, 12**
- mirtazapine **295**
 anxiety in schizophrenia patients **52**
 art of psychopharmacology/pearls **298**
 dosages and kinetics **297**
 drug interactions **297**
 initial workup/laboratory tests **296**
 mechanisms of action **295**
 medication-related psychosis **67–68**
 plasma concentrations **296**
 treatment monitoring **297**
 treatment response and side effects **296**
- mixed amphetamine salts **427**
 art of psychopharmacology/pearls **433**
 dosages and kinetics **430**
 drug interactions **431–432**
 initial workup/laboratory tests **429**
 mechanisms of action **428**
 plasma concentrations **428**
 treatment monitoring **430**
 treatment response and side effects **428**
- moclobemide **331**
 art of psychopharmacology/pearls **333**
 dosages and kinetics **333**
 drug interactions **333**
 initial workup/laboratory tests **332**
 mechanisms of action **331**
 plasma concentrations **332**
 treatment monitoring **332**
 treatment response and side effects **332**
- modafinil **440**
 art of psychopharmacology/pearls **445**
 cytochrome P450 induction/inhibition **492**
 dosages and kinetics **443**
 drug interactions **444**
 initial workup/laboratory tests **442**
 mechanisms of action **440**
 plasma concentrations **441**
 treatment monitoring **443**
 treatment response and side effects **441**
- molindone, children/adolescents **73–74**
- mood stabilizers; *see also* lithium; valproic acid
 plasma concentrations **13, 14, 490**
 positive psychotic symptoms **8**
 SAD-BT patients – acute manic phase **42–45, 45**
 SAD-BT patients – maintenance phase **45–47**

- weight gain when combined with antidepressants 39, 42
- motivation for change, substance use disorders 90
- motivational interviewing 32
- naltrexone
 - alcohol use disorder **93**
 - opioid use disorder **94**
- negative symptoms 34; *see also* depression; suicidality
- neoplasms, psychosis in children/adolescents **68–69**
- neurocognitive disorders, behavioral disturbances 99
- neurocognitive impairments, screening tools/evaluation instruments for substance use disorders 88
- neurodevelopmental disorders (NDD), children/adolescents **62–65, 65**
- neurotransmitters/receptors, effects of medication *see under specific drugs* (mechanism of action)
- neutrophil count *see* absolute neutrophil count
- nicotine use disorder *see* tobacco use disorder
- non-pharmacological treatments; *see also* electroconvulsive therapy
 - bright light therapy 82–83
 - deep brain stimulation 82, 83
 - repetitive transcranial magnetic stimulation 81, 83
 - transcranial direct current stimulation 82, 83
 - vagal nerve stimulation 82, 83
- nortriptyline **324**
 - art of psychopharmacology/pearls **307, 326**
 - dosages and kinetics **306, 326**
 - drug interactions **326, 501**
 - initial workup/laboratory tests **325**
 - mechanisms of action **324**
 - medication-related psychosis **67–68**
 - plasma concentrations **305, 325**
 - treatment monitoring **325**
 - treatment response and side effects **325**
- NSAIDs (nonsteroidal anti-inflammatory drugs), medication-related psychosis **67–68**
- obsessive-compulsive disorder (OCD)
 - differential diagnosis of anxiety symptoms 54
 - differential diagnoses in children/adolescents 64
 - evaluation instruments for children/adolescents **62–64**
- olanzapine **159**
 - aggression 24–25, 27
 - art of psychopharmacology/pearls **164**
 - children/adolescents **73–74**
 - contraindications/medical precautions **163**
 - dosages and kinetics **18–19, 45–46, 162**
 - drug interactions **163**
 - geriatric patients 7
 - initial workup/laboratory tests **161**
 - long-acting injectable **16–19, 45–46**
 - mechanisms of action **160**
 - plasma concentrations 12–13, **160, 489**
 - point of futility 6
 - positive psychotic symptoms 6
 - psychomotor agitation **503–505**
 - response rates in treatment-resistant psychosis **23**
 - SAD-BT patients – acute manic phase **43**
 - SAD-BT patients – maintenance phase **47–48**
 - treatment monitoring **162**
 - treatment response and side effects **160, 161**
- omega-3 fatty acids 36, 61
- opioid use disorder 88–89, **94**
- orexin receptor antagonists 57
- organized aggression/violence 24, 38, 38, 40
- oxazepam **377**
 - art of psychopharmacology/pearls **380**
 - dosages and kinetics **379**
 - drug interactions **379**
 - initial workup/laboratory tests **378**
 - mechanisms of action **377**
 - plasma concentrations **378**
 - treatment monitoring **379**
 - treatment response and side effects **378**
- oxcarbazepine, plasma concentrations 13
- paliperidone **165**
 - art of psychopharmacology/pearls **169**
 - children/adolescents **73–74**
 - contraindications/medical precautions **169**
 - dosages and kinetics **18–19, 45–46, 168**
 - drug interactions **168**
 - initial workup/laboratory tests **167**
 - long-acting injectable **6, 16–19, 45–46**
 - mechanisms of action **166**
 - plasma concentrations **166, 489**
 - plasma levels relative to drug dosage **12–13**
 - psychomotor agitation 505
 - treatment monitoring **167**
 - treatment response and side effects **166**
- PANSS (Positive and Negative Syndrome Scale)
 - anxiety in schizophrenia patients 51
 - repetitive transcranial magnetic stimulation 81
 - treatment-resistant schizophrenia 24, **25–26, 26**

- paroxetine **256**
 art of psychopharmacology/pearls **259**
 dosages and kinetics **258**
 drug interactions **136, 259, 412–413, 501**
 initial workup/laboratory tests **257**
 mechanisms of action **256**
 medication-related psychosis **67–68**
 plasma concentrations **257**
 treatment monitoring **258**
 treatment response and side effects **257**
- PCP (phencyclidine) **65, 66–67, 88–89**
- PDMPs *see* prescription drug monitoring programs
- pediatrics *see* children/adolescents
- penicillin, medication-related psychosis **67–68**
- perphenazine **121**
 art of psychopharmacology/pearls **124**
 dosages and kinetics **123**
 drug interactions **123**
 initial workup/laboratory tests **122**
 mechanisms of action **121**
 plasma concentrations **12–13, 122, 489**
 treatment monitoring **123**
 treatment response and side effects **122**
- persistent aggression/violence *see* aggression and violence
- PFC (prefrontal cortex), behavioral disturbances **98**
- pharmacotherapy *see* psychopharmacological approaches
- phenelzine **335**
 art of psychopharmacology/pearls **337**
 dosages and kinetics **336**
 drug interactions **337**
 initial workup/laboratory tests **336**
 mechanisms of action **335**
 plasma concentrations **335**
 treatment monitoring **336**
 treatment response and side effects **335, 336**
- phenytoin
 cytochrome P450 induction/inhibition **492**
 drug interactions **412–413, 418–419**
- phototherapy **82–83**
- plasma drug concentrations xxii, 12, 14; *see also specific drugs*
 antipsychotics **12–13, 489**
 levels relative to drug dosage **12–13**
 long-acting injectable antipsychotics **20, 20**
 maximum/minimal response thresholds **12–13, 12**
 mood stabilizers **13, 14, 490**
 persistent aggression and violence **39**
 and treatment response **466**
- point of futility
 long-acting injectable antipsychotics **20**
 medication **6**
 plasma drug concentration measurements **12–13**
- polypharmacy/combination regimens
 children/adolescents **73–74**
 depressed and suicidal schizophrenia **35**
 SAD-BT patients **47–48**
 treatment-resistant schizophrenia **23**
- Positive and Negative Syndrome Scale *see* PANSS
- positive psychotic symptoms xxii, 3, 10
 adjunctive medication **7, 8**
 dementia patients **7, 7**
 dopamine and glutamate hypotheses **3**
 initial evaluation **3–4, 4, 5**
 PRN or STAT medications **9, 9**
 treatment approaches **6, 6**
 treatment resistance **10**
- post-traumatic stress disorder *see* PTSD
- pramipexole **35, 497–498**
- prazosin, geriatric patients **7**
- predatory aggression/violence **24, 38, 38, 40**
- prefrontal cortex (PFC), behavioral disturbances **98**
- prescription drug monitoring programs (PDMPs), substance use disorders **88**
- pro re nata (PRN) medications
 positive psychotic symptoms **9, 9**
 psychomotor agitation **504**
- problematic behaviors *see* behavioral disturbances
- procaine penicillin, medication-related psychosis **67–68**
- prolactin, treating elevated **497–498**
- propranolol
 anxiety in schizophrenia patients **52**
 behavioral disturbances **100–101**
- psychomotor agitation algorithm **502–506**
 acute intervention phase **503–505**
 maintenance phase **505–506**
 stabilization phase **505**
- psychopharmacological approaches; *see also specific drugs*
 alcohol use disorder **93**
 behavioral disturbances **100–101**
 bipolar depression **35**
 opioid use disorder **94**
 persistent aggression and violence **38–40**
 positive psychotic symptoms **5, 6, 6**
 primary anxiety/depression in schizophrenia **54**
 SAD-BT patients – acute manic phase **42–44**
 SAD-BT patients – maintenance phase **45–47**
 substance use disorders **91**
 suicidality in schizophrenia **34, 35**

- tobacco use disorder 91–92, **91–92**
- Psychopharmacology Resource Network **xxi**
- psychosocial interventions
 - behavioral disturbances 99
 - children/adolescents 74–75, 75
 - early-onset schizophrenia 61
 - substance use disorders 90
- psychosocial stressors, aggressive behavior 39
- psychotic aggression/violence 24, 38, 39
- PTSD (post-traumatic stress disorder), children/adolescents **62–64**, 64

- QT interval, formulas to correct for **491**
- quetiapine **170**
 - art of psychopharmacology/pearls **174**
 - bipolar depression **35**
 - children/adolescents **71–73**, **73–74**
 - contraindications/medical precautions **173**
 - dosages and kinetics **173**
 - geriatric patients **7**
 - initial workup/laboratory tests **172**
 - mechanisms of action **171**
 - plasma concentrations **171**
 - SAD-BT patients – maintenance phase **47–48**
 - treatment monitoring **172**
 - treatment response and side effects **171**
- quinidine *see* dextromethorphan/quinidine

- ramelteon **58**, **397**
 - art of psychopharmacology/pearls **400**
 - dosages and kinetics **399**
 - drug interactions **399**
 - initial workup/laboratory tests **398**
 - insomnia and sleep disturbance **57**
 - mechanisms of action **397**
 - plasma concentrations **397**
 - treatment monitoring **398**
 - treatment response and side effects **397**, **398**
- rapid transcranial magnetic stimulation 36
- relapse prediction, anxiety in schizophrenia 51–52
- relapse prevention, electroconvulsive therapy 81
- Relapse Risk Assessment for Schizophrenia Patients 52
- repetitive transcranial magnetic stimulation (RTMS) 81, 83
- resistance to treatment *see* treatment resistance
- rifampin, cytochrome P450 induction/inhibition **492**
- risperidone **175**
 - art of psychopharmacology/pearls **179**
 - children/adolescents **73–74**
 - contraindications/medical precautions **179**
 - dosages and kinetics **18–19**, **45–46**, **178**
 - drug interactions **178**
 - geriatric patients **7**
 - initial workup/laboratory tests **177**
 - long-acting injectable **16–18**, **18–19**, **45–46**
 - mechanisms of action **176**
 - plasma concentrations **176**, **489**
 - plasma levels relative to drug dosage **12–13**
 - psychomotor agitation 503–505
 - treatment monitoring **177**
 - treatment response and side effects **176**
- rivastigmine **469**
 - art of psychopharmacology/pearls **474–475**
 - dosages and kinetics **472**
 - drug interactions **473**
 - initial workup/laboratory tests **471**
 - mechanisms of action **469**
 - plasma concentrations **470**
 - treatment monitoring **471**
 - treatment response and side effects **470**

- S-adenosylmethionine (SAM-E), schizophrenia 36
- salicylates, medication-related psychosis **67–68**
- Scale for the Assessment of Negative Symptoms (SANS) 81
- schizoaffective disorder, bipolar type (SAD-BT) **xxii**, 48
 - adherence issues 47
 - antidepressant contraindications 47, 52
 - antipsychotics, acute manic phase 42–44
 - antipsychotics, maintenance phase 45–47, **47–48**
 - anxiety associations 53
 - kinetics of long-acting injectable antipsychotics **45–46**
 - mood stabilizers, acute manic phase 42, 42–45, **45**
 - mood stabilizers, maintenance phase 45–47
- schizoaffective disorder, treatment-resistant 27
- Schizophrenia Patient Outcomes Research Team 91
- schizophrenia, treatment-resistant **xxii**, 22, 32
 - aggression 24–26, 25–26, 27
 - antipsychotic response rates 23, **23**
 - benzodiazepine contraindications 51, 52, 53–54, 56
 - categories of violence 24
 - childhood-onset 61
 - gold standard treatment 23
 - initiating clozapine treatment 28, 28–31
 - motivational interviewing 32
 - PANSS scores 24, **25–26**
 - polypharmacy/combination regimens 23
 - SAD-BT patients 42–43
 - suicidality 24, 24
 - time delays in initiating treatment 23
 - treatment maintenance 31, **32**
 - treatment monitoring 23, **29**, **31**, **32**

- screening tools
 children/adolescents **62–64**
 substance use disorders 87–89, **90**
- sedatives; *see also specific drugs*
 positive psychotic symptoms **8**
 and risk of psychotic illness **86–87**
- seizures, psychosis in children/adolescents
68–69
- selegiline *see* transdermal selegiline
- serotonin antagonists, anxiety in schizophrenia
 52; *see also* SSRIs; *and under specific drugs* (mechanism of action)
- serotonin syndrome, drug interactions **501**
- sertraline **261**
 art of psychopharmacology/pearls **264**
 dosages and kinetics **263**
 drug interactions **263, 501**
 initial workup/laboratory tests **262**
 mechanisms of action **261**
 medication-related psychosis **67–68**
 plasma concentrations **262**
 treatment monitoring **262**
 treatment response and side effects **262**
- sleep disturbance *see* insomnia and sleep disturbance
- SNRIs (serotonin and norepinephrine reuptake inhibitors), drug interactions **501**; *see also specific drugs*
- SSRIs (selective serotonin reuptake inhibitors); *see also specific drugs*
 behavioral disturbances 99
 contraindications/medical precautions 51
 drug interactions **501**
 early-onset schizophrenia 61
 geriatric patients **7**
 medication-related psychosis **67–68**
 positive psychotic symptoms **8**
 primary anxiety/depression in schizophrenia 54
 psychomotor agitation 504
- St. John's Wort **36, 492**
- STAT (standard therapy plus active therapy), positive psychotic symptoms **9, 9**
- Stevens-Johnson Syndrome, carbamazepine-induced 98
- stimulant use disorder, treatment approaches 95; *see also* cocaine; methamphetamine
- substance use disorders xxii, 86, 95
 alcohol 86–87, **92, 93**
 cannabis 95
 differential diagnoses in children/adolescents 65–66
 evaluation instruments for children/adolescents **62–64**
 motivation for change 90
 opioid use disorder **94, 94**
 pathways to aggression and violence **87**
 psychopharmacological approaches 91
 psychosocial interventions 90
 and risk of aggression and violence 87
 and risk of psychotic illness 86, **86–87**
 screening tools 87–89, **90**
 stimulants 95
 tobacco 199.150 **91–92, 91–92**
- suicidality xxii, 34, 36
 antidepressants 34, **35**
 antipsychotics 34, **35**
 benzodiazepine risks 51, 52, 53–54, 56
 early-onset schizophrenia 61
 lithium 34
 other treatments 36
 polypharmacy/combination regimens **35**
 treatment-resistant schizophrenia 24, **24**
- sulfonamides, medication-related psychosis **67–68**
- suvorexant 57, **58**
- synthetic cathinones, use in children/adolescents 66–67
- tasimelteon **58, 401**
 art of psychopharmacology/pearls **403**
 dosages and kinetics **402**
 drug interactions **403**
 initial workup/laboratory tests **402**
 insomnia and sleep disturbance **57, 58**
 mechanisms of action **401**
 plasma concentrations **401**
 treatment monitoring **402**
 treatment response and side effects **401, 402**
- TBI *see* traumatic brain injury
- TDCS *see* transcranial direct current stimulation
- temazepam **381**
 art of psychopharmacology/pearls **384**
 dosages and kinetics **383**
 drug interactions **383**
 initial workup/laboratory tests **382**
 mechanisms of action **381**
 plasma concentrations **382**
 treatment monitoring **383**
 treatment response and side effects **382**
- THC (tetra-hydro-cannabinol) *see* cannabis
- therapeutic thresholds, LAI antipsychotics **20**
- thiothixene **125**
 art of psychopharmacology/pearls **128**
 dosages and kinetics **127**
 drug interactions **127**
 initial workup/laboratory tests **126**
 mechanisms of action **125**
 plasma concentrations **126**
 treatment monitoring **127**

- treatment response and side effects **126**
- tobacco use disorder
 - and risk of psychotic illness **86–87**
 - treatment approaches 91, **91–92**
- tolerability thresholds, LAI antipsychotics **20**
- toxic exposures, psychosis in children/adolescents **68–69**
- transcranial direct current stimulation (TDCS) 82, 83
- transdermal selegiline **338**
 - art of psychopharmacology/pearls **340**
 - dosages and kinetics **340**
 - drug interactions **340**
 - initial workup/laboratory tests **339**
 - mechanisms of action **338**
 - plasma concentrations **339**
 - treatment monitoring **339**
 - treatment response and side effects **339**
- tranylcypromine **342**
 - art of psychopharmacology/pearls **344**
 - dosages and kinetics **343**
 - drug interactions **344**
 - initial workup/laboratory tests **343**
 - mechanisms of action **342**
 - plasma concentrations **342**
 - treatment monitoring **343**
 - treatment response and side effects **342, 343**
- traumatic brain injury (TBI)
 - behavioral disturbances 98–99
 - psychosis in children/adolescents **68–69**
- trazodone **299**
 - art of psychopharmacology/pearls **303**
 - dosages and kinetics **301**
 - drug interactions **302, 501**
 - geriatric patients **7**
 - initial workup/laboratory tests **300**
 - mechanisms of action **299**
 - plasma concentrations **300**
 - treatment monitoring **301**
 - treatment response and side effects **300**
- treatment approaches *see* non-pharmacological treatments; psychopharmacological approaches
- Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) study **73**
- treatment resistance 80; *see also specific disorders*
 - definition according to Kane Criteria **22**
 - mania **27, 28**
 - positive psychotic symptoms **10**
 - schizoaffective disorder **27**
- tricyclic antidepressants; *see also specific drugs*
 - drug interactions **501**
 - medication-related psychosis **67–68**
- trifluoperazine **129**
 - art of psychopharmacology/pearls **132**
 - dosages and kinetics **131**
 - drug interactions **131**
 - initial workup/laboratory tests **130**
 - mechanisms of action **129**
 - plasma concentrations **130**
 - treatment monitoring **131**
 - treatment response and side effects **130**
- trihexyphenidyl **213**
 - art of psychopharmacology/pearls **216**
 - dosages and kinetics **215**
 - drug interactions **215**
 - initial workup/laboratory tests **214**
 - mechanisms of action **213**
 - plasma concentrations **213**
 - treatment monitoring **215**
 - treatment response and side effects **213, 214**
- tyramine, foods high in **499–500**
- urine sampling; *see also under specific drugs*
 - (initial workup/laboratory tests)
 - psychosis in children/adolescents **70**
 - substance use disorders **88–89, 89**
- vagal nerve stimulation (VNS) 82, 83
- valproate
 - behavioral disturbances **99**
 - drug interactions **485**
 - SAD-BT patients – acute manic phase **44–45**
- valproic acid (VPA) **233**
 - art of psychopharmacology/pearls **237**
 - contraindications/medical precautions **236**
 - dosages and kinetics **235**
 - drug interactions **236**
 - geriatric patients **7**
 - initial workup/laboratory tests **234**
 - loading **496**
 - mechanisms of action **233**
 - plasma concentrations **13, 14, 234, 490**
 - psychomotor agitation **504, 505**
 - SAD-BT patients – acute manic phase **42–44**
 - treatment monitoring **235**
 - treatment response and side effects **234**
- varenicline, tobacco use disorder **91–92**
- venlafaxine **286**
 - art of psychopharmacology/pearls **289**
 - dosages and kinetics **288**
 - drug interactions **288, 412–413, 501**
 - initial workup/laboratory tests **287**
 - mechanisms of action **286**
 - plasma concentrations **287**
 - treatment monitoring **288**
 - treatment response and side effects **287**
- Veterans Health Administration (VHA) study, US **99**

- vilazodone **265**
 art of psychopharmacology/pearls **268**
 dosages and kinetics **267**
 drug interactions **267, 501**
 initial workup/laboratory tests **266**
 mechanisms of action **265**
 plasma concentrations **266**
 treatment monitoring **266**
 treatment response and side effects **266**
- violence *see* aggression and violence
- VNS (vagal nerve stimulation) 82, 83
- vortioxetine **269**
 art of psychopharmacology/pearls **272**
 dosages and kinetics **271**
 drug interactions **271, 501**
 initial workup/laboratory tests **270**
 mechanisms of action **269**
 plasma concentrations **270**
 treatment monitoring **270**
 treatment response and side effects **270**
- VPA *see* valproic acid
- weight gain, mood stabilizers when combined
 with antidepressants 39, 42
- zaleplon 56–57, **58, 385**
 art of psychopharmacology/pearls **388**
 dosages and kinetics **387**
 drug interactions **388**
- initial workup/laboratory tests **386**
 mechanisms of action **385**
 plasma concentrations **386**
 treatment monitoring **387**
 treatment response and side effects **386**
- Z-drugs (general) 56–57, **58**
- ziprasidone **180**
 art of psychopharmacology/pearls **184**
 children/adolescents **71–73**
 contraindications/medical precautions
183
 dosages and kinetics **183**
 drug interactions **183, 501**
 initial workup/laboratory tests **182**
 mechanisms of action **180**
 plasma concentrations **181**
 SAD-BT patients **43**
 treatment monitoring **182**
 treatment response and side effects **181**
- zolpidem **56–57, 58, 389**
 art of psychopharmacology/pearls **392**
 dosages and kinetics **391**
 drug interactions **392**
 initial workup/laboratory tests **390**
 mechanisms of action **389**
 plasma concentrations **390**
 psychomotor agitation 504
 treatment monitoring **391**
 treatment response and side effects **390**